FDMT - 4D Molecular Therapeutics Goes Neck To Neck With Rival Shares New Phase 2 Data For Its Wet AMD Candidate | Benzinga
Wednesday, 4D Molecular Therapeutics, Inc.(NASDAQ:FDMT) unveiled interim 24-week data from the Population Extension cohort of its PRISM Phase 2 Clinical Trial.
The trial evaluates intravitreal 4D-150 in a broad wet AMD patient population.
The findings were presented at the American Society of Retina Specialists Annual Scientific Meeting.
The Phase 2 PRISM Population Extension cohort evaluated 45 wet AMD patients previously treated with anti-VEGF injections, with 30 patients at 3E10 vg/eye (the planned ...